HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer

The purpose of this clinical trial is to learn the safety and efficacy of HDAC inhibitors in combination with neoadjuvant immunochemotherapy compared to neoadjuvant therapy in the treatment of locally advanced colon cancer. The main questions it aims to answer are: Can HDAC inhibitors combined with neoadjuvant immunochemotherapy improve the rate of pCR and complete resection in patients? Are HDAC inhibitors combined with neoadjuvant immunochemotherapy safe and reliable? Does the combination of HDAC inhibitors and neoadjuvant immunochemotherapy achieve a better long-term prognosis than neoadjuvant therapy?

NCT Number	NCT06709885
Lead Sponsor	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Collaborators: Southwest Hospital, China, Xinqiao Hospital of Chongqing, First Affiliated Hospital of Chongqing Medical University, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing University Cancer Hospital, Chongqing General Hospital, Chongqing Traditional Chinese Medicine Hospital, Chongqing Shapingba District People's Hospital, Chongqing Seventh People's Hospital, Chongqing Renji Hospital, University of Chinese Academy of Sciences, The 13th People's Hospital of Chongqing
Conditions	Colon Adenocarcinoma
Enrollment	100 participants
Start Date	2024-10-15
Primary Completion	2025-09-30 (estimated)
Study Completion	2027-09-30 (estimated)
Updated on ClinicalTrials.gov	2024-11-29